Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 5/20 | 0.43 |
| ▸ | SCN1A | P35498 | 4/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31018033 | 0.87 | SCN8A (0.45) | SCN8ASCN1ASCN5A | |
| SCHEMBL21783515 | 0.87 | SCN8A (0.45) | SCN8ASCN1ASCN5A | |
| SCHEMBL21783423 | 0.85 | SCN8A (0.43) | SCN8ASCN1ASCN5A | |
| SCHEMBL21777394 | 0.84 | SCN8A (0.32) | SCN8ASCN1ASCN5A | |
| SCHEMBL30045891 | 0.83 | SCN8A (0.43) | SCN8ASCN1ASCN5A | |
| SCHEMBL21783374 | 0.83 | SCN8A (0.43) | SCN8ASCN1ASCN5A | |
| SCHEMBL1094763 | 0.80 | SCN8A (0.46) | SCN8ASCN1ASCN5A | |
| SCHEMBL19614272 | 0.79 | SCN8A (0.50) | SCN8ASCN1ASCN5A | |
| SCHEMBL30662725 | 0.79 | SCN8A (0.50) | SCN8ASCN1ASCN5A | |
| SCHEMBL21783343 | 0.79 | SCN8A (0.43) | SCN8ASCN1ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112638879-B | Heteroaryl substituted sulfonamide compounds and their use as therapeutic agents | 泽农医药公司 | 2024-06-18 | — | — | CN | disclosed |
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. | 2023-05-02 | — | — | US | disclosed |
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. | 2023-05-02 | — | — | US | disclosed |
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. | 2023-05-02 | — | — | US | disclosed |
| US-20220348570-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2022-11-03 | — | — | US | disclosed |
| US-10981905-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-04-20 | — | — | US | disclosed |
| US-20200157089-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-05-21 | — | — | US | disclosed |
| WO-2020047323-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | WO | disclosed |
| US-20160220564-A1 | SUBSTITUTUED QUINOXALINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | SCN1A, SCN2A, SCN2B | SCN8A 6/4885SCN1A 1/4885SCN5A 7/4885 |
| US-20200157089-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN2A, SCN2B | SCN8A 6/4885SCN1A 1/4885SCN5A 7/4885 |
| US-20160220564-A1 | SUBSTITUTUED QUINOXALINES AS FGFR KINASE INHIBITORS | FGFR1, FGFR3, FGFR4 | SCN8A 3880/4885SCN1A 3289/4885SCN5A 2153/4885 |
| US-10981905-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | SCN1A, SCN2A, SCN2B | SCN8A 6/4885SCN1A 1/4885SCN5A 7/4885 |
| US-20220348570-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN2A, SCN2B | SCN8A 6/4885SCN1A 1/4885SCN5A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.